ReCode Therapeutics announced today that it closed a Series B extension financing round, adding $120 million in new funds. Menlo Park, California-based ReCode, which develops the selective organ targeting (SORT) lipid nanoparticle technology (LNP) delivery platform, has now raised $200 million total in the Series B. New investors Leaps by Bayer (the impact investment unit […]